Results: The final analysis comprised of 80 patients (male 58.8%; median age 60.6 years and 82.5% had an Eastern Cooperative Oncology Group performance status score ≥1 Chemotherapy included capecitabine plus oxaliplatin (58.7%); 5-fluorouracil / leucovorin (5-FU / LV) + oxaliplatin (11.3%), irinotecan plus 5-FU / LV (8.8%), capecitabine monotherapy (13.7%) and others (7.5%).